Ausgabe 2/2015
Inhalt (8 Artikel)
Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party
Jason Madan, Tony Ades, Pelham Barton, Laura Bojke, Ernest Choy, Philip Helliwell, Paresh Jobanputra, Ken Stein, Andrew Stevens, Jonathan Tosh, Suzanne Verstappen, Allan Wailoo
Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
Nicole M. Engel-Nitz, Sarika Ogale, Mahesh Kulakodlu
Influence of Continuing Medical Education on Rheumatologists’ Performance on National Quality Measures for Rheumatoid Arthritis
Tamar Sapir, Erica Rusie, Laurence Greene, Jinoos Yazdany, Mark L. Robbins, Eric M. Ruderman, Jeffrey D. Carter, Barry Patel, Kathleen Moreo
Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based Registry
Dimitrios A. Pappas, Jeffrey D. Kent, Jeffrey D. Greenberg, Marc A. Mason, Joel M. Kremer, Robert J. Holt
Biologics Prescribing for Rheumatoid Arthritis in Older Patients: A Single-Center Retrospective Cross-Sectional Study
Klara Morsley, Thomas Kilner, Alan Steuer
Predictors of Atherosclerosis in Ankylosing Spondylitis
Inderjeet Verma, Pawan Krishan, Ashit Syngle
Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC–MS/MS
Hong-wei Fan, Zhi-xiang Ma, Jing Chen, Xing-ye Yang, Jun-lin Cheng, Ying-bin Li